News round-up for 5-9 June by DDW Digital Content Editor Diana Spencer.
There has been some interesting news related to clinical trials this week, with the announcement that the FDA has published draft guidance to modernise the design and conduct of studies, and the failure of Bellerophon Therapeutics’ Phase III study in fibrotic Interstitial Lung Disease.
The top stories:
Successful Phase I results for cardioprotective drug
Serca Pharmaceuticals has presented data on a novel approach to modulate the beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility.
Novel glycan-coated nanoparticle enters trials for geographic atrophy
Aviceda Therapeutics has dosed the first patient in its Phase II SIGLEC trial investigating AVD-104 as a treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
FDA announces additional steps to modernise clinical trials
The US Food and Drug Administration has published draft guidance with updated recommendations for good clinical practices (GCPs) to modernise the design and conduct of clinical trials.
Phase III pulmonary fibrosis drug trial fails
Bellerophon Therapeutics has announced it will close its Phase III study of INOpulse, its treatment for fibrotic Interstitial Lung Disease (fILD), after the trail failed to meet its primary endpoint.
Promising results for disitamab vedotin in bladder cancer
RemeGen announced the latest clinical research results on disitamab vedotin (RC48) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
